# Tocilizumab

## Actemra inj 162mg/0.9mL

| TAH Drug Code      | [IACTM](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IACTM)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | 1. **Rheumatoid Arthritis (RA)** Actemra in combination with methotrexate (MTX) is indicated for the treatment of adults with moderate to severe rheumatoid arthritis who have had an inadequate response to or are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs) or tumor necrosis factor (TNF) antagonists. In patients who cannot tolerate MTX or are not suitable for continued MTX treatment， ActemraR can be used as monotherapy. When ActemraR is combined with MTX， it has been shown to slow the progression of joint damage， as measured by X-rays， and improve physical function， as assessed by the HAQ-DI scale. 2. **Giant Cell Arteritis (GCA)** Actemra is indicated for the treatment of adults with giant cell arteritis (GCA). |
| Dosing             | SC， rheumatoid arthritis， giant cell arteritis: <100 kg 162 mg once every other week， increase to 162 mg once a week based on clinical response; > or =100 kg 162 mg once a week.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Contraindications  | Hypersensitivity to tocilizumab.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Adverse Effects    | Upper resp tract infections， cellulitis， oral herpes simplex， herpes zoster; abdominal pain， mouth ulceration， gastritis; rash， pruritus， urticaria; headache， dizziness; increased hepatic transaminases， increased wt; HTN; leucopenia， neutropenia; hypercholesterolaemia; peripheral oedema， hypersensitivity reaction， inj site reaction; cough， dyspnoea; conjunctivitis.                                                                                                                                                                                                                                                                                                                                                                                      |
| Pregnancy          | No (Limited) Human Data – Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| More Info          | [UpToDate](https://www.uptodate.com/contents/tocilizumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

## Actemra Infusion 80mg/4mL/Vial (限Covid-19)

| TAH Drug Code      | [IACTMV](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IACTMV)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | 1. Rheumatoid Arthritis (RA). 2. Rheumatoid Arthritis (RA) – RA not previously treated with MTX. 3. Polyarticular Juvenile Idiopathic Arthritis (PJIA) in children over 2 years old. 4. Systemic Juvenile Idiopathic Arthritis (SJIA) in children over 2 years old. 5. Cytokine Release Syndrome (CRS). 6. Coronavirus Disease (COVID-19， Severe Special Infectious Pneumonia) Indicated for the treatment of hospitalized adult patients with COVID-19 receiving systemic corticosteroid therapy and requiring oxygen supplementation， non-invasive or invasive mechanical ventilation， or Extracorporeal Membrane Oxygenation (ECMO).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Dosing             | - COVID-19: Recommended dose for hospitalized adults: 8 mg/kg via a single 60-minute IV infusion， not exceeding 800 mg. May give an additional dose at least 8 hours after the first if symptoms worsen or don’t improve. Subcutaneous administration is not approved for COVID-19. - Rheumatoid Arthritis: Actemra can be used alone or with methotrexate (MTX). Recommended dose: 4 mg/kg intravenous (IV) infusion over 60 minutes Q4W; may adjust to 8 mg/kg based on clinical response. Adjust to 4 mg/kg if lab changes such as liver enzyme elevation， neutropenia， or thrombocytopenia occur. Do not exceed 800 mg per infusion. - Polyarticular Juvenile Idiopathic Arthritis (PJIA): Actemra can be used alone or with MTX. Recommended dose Q4W via 60-minute IV infusion: <30 kg: 10 mg/kg; >=30 kg: 8 mg/kg - Systemic Juvenile Idiopathic Arthritis (SJIA): Actemra can be used alone or with MTX. Recommended dose Q2W via 60-minute IV infusion: <30 kg: 12 mg/kg; >=30 kg: 8 mg/kg. - Cytokine Release Syndrome (CRS): IV administration only. Recommended dose for CRS via 60-minute IV infusion: <30 kg: 12 mg/kg; >=30 kg: 8 mg/kg. May administer up to 3 additional doses if no improvement， with at least 8 hours between doses. Do not exceed an 800 mg dose per infusion. Subcutaneous administration is not approved for CRS. - Avoid combination. No clinical data on combining Actemra with other biological DMARDs; risk of increased immunosuppression and infection. - Do not start Actemra in patients with ANC <2，000/mm^3 or 1000/mm^3 (COVID-19)， platelet count <100，000/mm^3 or 50，000/mm^3 (COVID-19)， or ALT/AST >1.5 times ULN or >10 times ULN (COVID-19). - Patients with severe/life-threatening CRS may have cytopenias or elevated ALT/AST due to chemotherapy or CRS. Evaluate benefits vs. risks of short-term Actemra use. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Contraindications  | Actemra is contraindicated in patients with a known hypersensitivity to tocilizumab or to any of the excipients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Adverse Effects    | Common: Hypertension (Adult， 4-7%)， Injection site disorder (Rheumatoid arthritis， 2.4-10.1% ; polyarticular juvenile idiopathic arthritis， 28.8% ; systemic juvenile idiopathic arthritis， 41.2%)， Rash (Rheumatoid arthritis， 2-4%)， Constipation (COVID-19， 6-13%)， Diarrhea (Adults， COVID-19， 4-6% ; Pediatric， >5%)， Nausea (COVID-19， 3-4%)， Upper abdominal pain (Adult， 2-3%)， ALT/SGPT level raised (COVID-19， 3% ; rheumatoid arthritis， 0.7-48%; polyarticular or systemic juvenile idiopathic arthritis， 4-13%)， Aspartate aminotransferase serum level above reference range (Rheumatoid arthritis， 0.1-41%; polyarticular or systemic juvenile idiopathic arthritis， <1-5%)， Dizziness (Adult， 2-3%)， Headache (Adults， 3-7%; pediatric， >5%)， Insomnia (COVID-19， 4-5%)， Anxiety (COVID-19， 3-6%)， Nasopharyngitis (Rheumatoid arthritis， 4-7%; systemic juvenile idiopathic arthritis， 5% or higher)， Infusion reaction (Rheumatoid arthritis， 7-8%; polyarticular juvenile idiopathic arthritis， 16-20.2%). Serious: Septic shock (COVID-19， 6%)， Gastrointestinal perforation， Pancreatitis， Neutropenia (Rheumatoid arthritis， 1.8-3.7% ; polyarticular or systemic juvenile idiopathic arthritis， 7-15.4%)， Thrombocytopenia (Up to 4%)， Hepatotoxicity， Anaphylaxis， Hypersensitivity reaction (Up to 0.9%)， Opportunistic infection， Tuberculosis， Upper respiratory infection (Rheumatoid arthritis， 6-8%; systemic juvenile idiopathic arthritis， 5% or higher)， Cancer， Sepsis， Severe infectious disease.                                                                                                                                                                                                                                                                                       |
| Pregnancy          | No (Limited) Human Data – Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| More Info          | [UpToDate](https://www.uptodate.com/contents/tocilizumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

## Actemra Infusion 200mg/10mL/Vial(限Covid-19)

| TAH Drug Code      | [IACTMV10](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IACTMV10)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | 1. Rheumatoid Arthritis (RA). 2. Rheumatoid Arthritis (RA) – RA not previously treated with MTX. 3. Polyarticular Juvenile Idiopathic Arthritis (PJIA) in children over 2 years old. 4. Systemic Juvenile Idiopathic Arthritis (SJIA) in children over 2 years old. 5. Cytokine Release Syndrome (CRS). 6. Coronavirus Disease (COVID-19， Severe Special Infectious Pneumonia) Indicated for the treatment of hospitalized adult patients with COVID-19 receiving systemic corticosteroid therapy and requiring oxygen supplementation， non-invasive or invasive mechanical ventilation， or Extracorporeal Membrane Oxygenation (ECMO).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Dosing             | - COVID-19: Recommended dose for hospitalized adults: 8 mg/kg via a single 60-minute IV infusion， not exceeding 800 mg. May give an additional dose at least 8 hours after the first if symptoms worsen or don’t improve. Subcutaneous administration is not approved for COVID-19. - Rheumatoid Arthritis: Actemra can be used alone or with methotrexate (MTX). Recommended dose: 4 mg/kg intravenous (IV) infusion over 60 minutes Q4W; may adjust to 8 mg/kg based on clinical response. Adjust to 4 mg/kg if lab changes such as liver enzyme elevation， neutropenia， or thrombocytopenia occur. Do not exceed 800 mg per infusion. - Polyarticular Juvenile Idiopathic Arthritis (PJIA): Actemra can be used alone or with MTX. Recommended dose Q4W via 60-minute IV infusion: <30 kg: 10 mg/kg; >=30 kg: 8 mg/kg - Systemic Juvenile Idiopathic Arthritis (SJIA): Actemra can be used alone or with MTX. Recommended dose Q2W via 60-minute IV infusion: <30 kg: 12 mg/kg; >=30 kg: 8 mg/kg. - Cytokine Release Syndrome (CRS): IV administration only. Recommended dose for CRS via 60-minute IV infusion: <30 kg: 12 mg/kg; >=30 kg: 8 mg/kg. May administer up to 3 additional doses if no improvement， with at least 8 hours between doses. Do not exceed an 800 mg dose per infusion. Subcutaneous administration is not approved for CRS. - Avoid combination. No clinical data on combining Actemra with other biological DMARDs; risk of increased immunosuppression and infection. - Do not start Actemra in patients with ANC <2，000/mm^3 or 1000/mm^3 (COVID-19)， platelet count <100，000/mm^3 or 50，000/mm^3 (COVID-19)， or ALT/AST >1.5 times ULN or >10 times ULN (COVID-19). - Patients with severe/life-threatening CRS may have cytopenias or elevated ALT/AST due to chemotherapy or CRS. Evaluate benefits vs. risks of short-term Actemra use. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Contraindications  | Actemra is contraindicated in patients with a known hypersensitivity to tocilizumab or to any of the excipients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Adverse Effects    | Common: Hypertension (Adult， 4-7%)， Injection site disorder (Rheumatoid arthritis， 2.4-10.1% ; polyarticular juvenile idiopathic arthritis， 28.8% ; systemic juvenile idiopathic arthritis， 41.2%)， Rash (Rheumatoid arthritis， 2-4%)， Constipation (COVID-19， 6-13%)， Diarrhea (Adults， COVID-19， 4-6% ; Pediatric， >5%)， Nausea (COVID-19， 3-4%)， Upper abdominal pain (Adult， 2-3%)， ALT/SGPT level raised (COVID-19， 3% ; rheumatoid arthritis， 0.7-48%; polyarticular or systemic juvenile idiopathic arthritis， 4-13%)， Aspartate aminotransferase serum level above reference range (Rheumatoid arthritis， 0.1-41%; polyarticular or systemic juvenile idiopathic arthritis， <1-5%)， Dizziness (Adult， 2-3%)， Headache (Adults， 3-7%; pediatric， >5%)， Insomnia (COVID-19， 4-5%)， Anxiety (COVID-19， 3-6%)， Nasopharyngitis (Rheumatoid arthritis， 4-7%; systemic juvenile idiopathic arthritis， 5% or higher)， Infusion reaction (Rheumatoid arthritis， 7-8%; polyarticular juvenile idiopathic arthritis， 16-20.2%). Serious: Septic shock (COVID-19， 6%)， Gastrointestinal perforation， Pancreatitis， Neutropenia (Rheumatoid arthritis， 1.8-3.7% ; polyarticular or systemic juvenile idiopathic arthritis， 7-15.4%)， Thrombocytopenia (Up to 4%)， Hepatotoxicity， Anaphylaxis， Hypersensitivity reaction (Up to 0.9%)， Opportunistic infection， Tuberculosis， Upper respiratory infection (Rheumatoid arthritis， 6-8%; systemic juvenile idiopathic arthritis， 5% or higher)， Cancer， Sepsis， Severe infectious disease.                                                                                                                                                                                                                                                                                       |
| Pregnancy          | No (Limited) Human Data – Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| More Info          | [UpToDate](https://www.uptodate.com/contents/tocilizumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

